The European Committee for Medicinal Products for Human Use endorsed approval of Amgen's Nplate, which treats a rare blood-clotting disease called idiopathic thrombocytopenia purpura. The drug, which works by boosting platelet production and preventing immune suppression in adults with chronic ITP, "will address an unmet medical need" in the region, an Amgen official said.

Full Story:

Related Summaries